Torrent Pharmaceuticals Future Growth

Future criteria checks 5/6

Torrent Pharmaceuticals is forecast to grow earnings and revenue by 21.3% and 11.6% per annum respectively. EPS is expected to grow by 21.6% per annum. Return on equity is forecast to be 33.4% in 3 years.

Key information

21.3%

Earnings growth rate

21.6%

EPS growth rate

Pharmaceuticals earnings growth	18.7%
Revenue growth rate	11.6%
Future return on equity	33.4%
Analyst coverage	Good
Last updated	24 Apr 2024

Recent future growth updates

The Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 28

Recent updates

Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings

Jan 07

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly

Nov 14

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Jun 01

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Mar 01

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Jul 25

Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture

Jun 02

Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

May 25

A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Feb 18

Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00

Jan 27

Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly

Jan 04

Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock

Dec 14

A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Nov 07

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Sep 30

Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?

Sep 01

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Jul 02

I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease

Jun 01

Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate

May 14

Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

Mar 23

The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More

Mar 02

Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?

Feb 10

Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?

Jan 19

Should You Be Impressed By Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) ROE?

Dec 29

Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?

Dec 08

Investors Who Bought Torrent Pharmaceuticals (NSE:TORNTPHARM) Shares Three Years Ago Are Now Up 118%

Nov 16

The Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 28

Here's Why We Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Well Worth Watching

Oct 07

Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Delivered A Better ROE Than Its Industry

Sep 16

Earnings and Revenue Growth Forecasts

NSEI:TORNTPHARM - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	150,725	30,361	31,749	N/A	1
3/31/2026	137,315	25,454	28,988	N/A	26
3/31/2025	121,959	20,552	24,913	N/A	28
3/31/2024	108,151	16,431	21,949	N/A	29
12/31/2023	104,742	14,942	N/A	N/A	N/A
9/30/2023	102,332	13,432	24,212	28,691	N/A
6/30/2023	98,642	12,692	N/A	N/A	N/A
3/31/2023	96,202	12,452	17,942	23,681	N/A
12/31/2022	92,580	8,312	N/A	N/A	N/A
9/30/2022	88,750	7,972	15,574	19,380	N/A
6/30/2022	87,210	8,012	N/A	N/A	N/A
3/31/2022	85,080	7,772	16,004	18,030	N/A
12/31/2021	83,158	12,189	N/A	N/A	N/A
9/30/2021	82,028	12,669	15,015	17,827	N/A
6/30/2021	80,828	12,609	N/A	N/A	N/A
3/31/2021	80,046	12,519	16,702	20,054	N/A
12/31/2020	80,143	12,417	N/A	N/A	N/A
9/30/2020	79,853	11,957	13,690	18,078	N/A
6/30/2020	79,733	11,297	N/A	N/A	N/A
3/31/2020	79,393	10,247	9,861	13,929	N/A
12/31/2019	78,488	5,593	N/A	N/A	N/A
9/30/2019	79,338	5,543	10,463	16,981	N/A
6/30/2019	78,228	4,893	N/A	N/A	N/A
3/31/2019	76,728	4,363	11,353	17,981	N/A
12/31/2018	75,141	8,161	N/A	N/A	N/A
9/30/2018	69,891	6,281	N/A	N/A	N/A
6/30/2018	65,121	6,531	N/A	N/A	N/A
3/31/2018	59,498	6,781	1,029	8,942	N/A
12/31/2017	56,727	6,556	N/A	N/A	N/A
9/30/2017	56,387	8,266	N/A	N/A	N/A
6/30/2017	56,387	8,296	N/A	N/A	N/A
3/31/2017	58,157	9,336	N/A	10,088	N/A
12/31/2016	59,154	10,014	N/A	N/A	N/A
9/30/2016	60,144	10,624	N/A	N/A	N/A
6/30/2016	62,744	13,644	N/A	N/A	N/A
3/31/2016	66,669	17,332	N/A	27,421	N/A
12/31/2015	63,315	16,299	N/A	N/A	N/A
9/30/2015	59,605	13,139	N/A	N/A	N/A
6/30/2015	54,865	9,439	N/A	N/A	N/A
3/31/2015	46,535	7,509	N/A	8,102	N/A
12/31/2014	47,247	8,649	N/A	N/A	N/A
9/30/2014	45,717	8,559	N/A	N/A	N/A
6/30/2014	43,267	7,709	N/A	N/A	N/A
3/31/2014	41,847	6,639	N/A	5,994	N/A
12/31/2013	38,291	5,308	N/A	N/A	N/A
9/30/2013	36,111	4,858	N/A	N/A	N/A
6/30/2013	33,781	4,798	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TORNTPHARM's forecast earnings growth (21.3% per year) is above the savings rate (6.7%).

Earnings vs Market: TORNTPHARM's earnings (21.3% per year) are forecast to grow faster than the Indian market (17.3% per year).

High Growth Earnings: TORNTPHARM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TORNTPHARM's revenue (11.6% per year) is forecast to grow faster than the Indian market (9.9% per year).

High Growth Revenue: TORNTPHARM's revenue (11.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: TORNTPHARM's Return on Equity is forecast to be high in 3 years time (33.4%)

Torrent Pharmaceuticals Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target increased by 7.1% to ₹2,427

Price target increased by 8.1% to ₹2,037

The Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Recent updates

Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark

Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024

Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director

Price target increased by 7.1% to ₹2,427

Upcoming dividend of ₹22.00 per share at 0.8% yield

Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00

Dividend increased to ₹22.00

Third quarter 2024 earnings: EPS exceeds analyst expectations

Torrent Pharmaceuticals Limited Announces Interim Dividend, Payable on or around 23 February, 2024

Torrent Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 02, 2024

Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Torrent Pharmaceuticals Limited to Report Q2, 2024 Results on Oct 23, 2023

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Food and Drug Administration Issues an Establishment Inspection Report for the Torrent Pharmaceuticals Limited's Manufacturing Facility At Dahej, Gujarat

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Price target increased by 8.1% to ₹2,037

Torrent Pharmaceuticals Limited Declares Final Dividend for the Financial Year Ended 31 March, 2023

Full year 2023 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 07, 2023

Torrent Pharmaceuticals Limited, Annual General Meeting, Aug 07, 2023

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Torrent Pharmaceuticals Limited Recommends Final Dividend, Payable on or Around 14 August, 2023

Full year 2023 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited to Report Q4, 2023 Results on May 30, 2023

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Torrent Pharmaceuticals Limited Approves an Interim Dividend, Payable on or Around 14 February 2023

Torrent Pharmaceuticals Limited to Report Q3, 2023 Results on Jan 25, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Torrent Pharmaceuticals Limited (BSE:500420) completed the acquisition of Curatio Healthcare (I) Pvt Ltd.

Torrent Pharmaceuticals Limited to Report Q2, 2023 Results on Oct 21, 2022

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Curatio Healthcare (I) Pvt Ltd for INR 20 billion.

Torrent Pharma Reportedly Set to Acquire Curatio

Less than half of directors are independent

Torrent Pharmaceuticals Announces Appointment of Aman Mehta as Director on the Board of Torrent Pharma from 1st August, 2022

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Torrent Pharmaceuticals Limited to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited, Annual General Meeting, Jul 29, 2022

Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture

Full year 2022 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).

Torrent Pharmaceuticals Limited Recommends Special Dividend, Payable on or Around 4 August, 2022

Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Insufficient new directors

Torrent, JB Chemicals Reportedly in Final Race to Acquire Curatio Healthcare

Insufficient new directors

Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio

A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly

Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock

A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Second quarter 2022 earnings released: EPS ₹18.63 (vs ₹18.32 in 2Q 2021)

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?

Full year 2021 earnings released: EPS ₹73.98 (vs ₹60.56 in FY 2020)

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Independent Non Executive Director recently bought ₹20m worth of stock

Upcoming dividend of ₹15.00 per share

Independent Non Executive Director recently bought ₹5.0m worth of stock

I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease

Torrent Pharmaceuticals Limited Recommends Final Dividend, Payable on or Around July 30, 2021